1. Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis
   Chiara Dalle Fratte et al, 2023, International Journal of Molecular Sciences CrossRef
2. Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia
   Gloria Ravegnini et al, 2016, Expert Opinion on Drug Metabolism & Toxicology CrossRef
3. ABCG2/BCRP: variants, transporter interaction profile of substrates and inhibitors
   Zsolt Safar et al, 2019, Expert Opinion on Drug Metabolism & Toxicology CrossRef
4. Introduction and Principles of Pharmacogenomics in Precision Medicine
   Weimin Cai et al, 2020, Pharmacogenomics in Precision Medicine CrossRef
5. A review of the literature on the relationships between genetic polymorphisms and chemotherapy-induced nausea and vomiting
   Komal P. Singh et al, 2018, Critical Reviews in Oncology/Hematology CrossRef
6. Revisiting the Effects of MDR1 Variants Using Computational Approaches
   Tal Gutman et al, 2024, Comparative Genomics CrossRef
7. Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer
   Elena Peruzzi et al, 2023, Biomedicine & Pharmacotherapy CrossRef
8. Comprehensive pharmacogenomics characterization of temozolomide response in gliomas
   Shuangmei Tong et al, 2021, European Journal of Pharmacology CrossRef
9. Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects
   Poe-Hirr Hsyu et al, 2017, European Journal of Clinical Pharmacology CrossRef
10. Genotypes Affecting the Pharmacokinetics of Anticancer Drugs
    Daphne Bertholee et al, 2017, Clinical Pharmacokinetics CrossRef
11. MDR1 Genotypes and Haplotypes Are Closely Associated with Postoperative Fentanyl Consumption in Patients Undergoing Radical Gastrectomy
    Fan Zhang et al, 2021, Journal of Nanomaterials CrossRef
12. Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
    Marialuisa Polillo et al, 2015, International Journal of Molecular Sciences CrossRef
13. ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis
    Q Zheng et al, 2015, The Pharmacogenomics Journal CrossRef
14. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia
    Natarajan Harivenkatesh et al, 2017, Pharmacological Research CrossRef
15. The Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: An Overview
    Sara Galimberti et al, 2016, Resistance to Tyrosine Kinase Inhibitors CrossRef
16. Safety and cardiovascular effects of multiple‐dose administration of aripiprazole and olanzapine in a randomised clinical trial
    Dora Koller et al, 2021, Human Psychopharmacology: Clinical and Experimental CrossRef
17. Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia
    Raquel Maia et al, 2018, Molecules CrossRef
18. Pharmacogenetics of Drug Transporters in Modulating Imatinib Disposition and Treatment Outcomes in Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Patients
    Sylvia Chen et al, 2016, Pharmacogenomics CrossRef
19. Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib
    Akimitsu Maeda et al, 2022, European Journal of Clinical Pharmacology CrossRef
20. Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia
    Laura Galeotti et al, 2017, Cancer Chemotherapy and Pharmacology CrossRef
21. Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia
    Islem Ben Hassine et al, 2017, Cancer Chemotherapy and Pharmacology CrossRef
22. MRP1 and P-glycoprotein expression assays would be useful in the additional detection of treatment non-responders in CML patients without ABL1 mutation
    Sang Hyuk Park et al, 2015, Leukemia Research CrossRef
23. Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics
    Dora Koller et al, 2021, Advances in Therapy CrossRef
24. ZNF139 increases multidrug resistance in gastric cancer cells by inhibiting miR-185
    Bibo Tan et al, 2018, Bioscience Reports CrossRef
25. Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: correlations with pharmacokinetics and MDR1 polymorphisms
    Milena Gusella et al, 2019, Cancer Chemotherapy and Pharmacology CrossRef
26. ABCB1 and BMI1 mRNA expression in patients with chronic myeloid leukemia: impact on imatinib efficacy
    Ahmed M. L. Bedewy et al, 2019, BLOOD RESEARCH CrossRef